A Retrospective Trial to Evaluate the Micra Pacemaker (Micra)

  • STATUS
    Recruiting
  • End date
    May 15, 2025
  • participants needed
    500
  • sponsor
    Hoag Memorial Hospital Presbyterian
Updated on 14 February 2022

Summary

This is a retrospective study of our patient population implanted with the Medtronic's Leadless single-chamber ventricular pacemakers.

Description

This protocol outlines the methods on the Micra Pacemaker. The Micra Transcatheter Pacemaker System is a miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart. The Micra device eliminates the need for a device pocket and insertion of a pacing lead, thereby eliminating lead and pocket related complications associated with traditional pacing systems while providing similar pacing benefits. The US Food and Drug Administration (FDA) approved the Micra system on April 6, 2016, for the following conditions:

  • symptomatic paroxysmal or permanent high-grade atrioventricular block (AV) in the presence of atrial fibrillation (AF)
  • symptomatic paroxysmal or permanent high-grade AV block in the absence of AF, as an alternative to dual chamber pacing, when atrial lead placement is considered difficult, high risk, or not deemed necessary for effective therapy
  • symptomatic bradycardia-tachycardia syndrome or sinus node dysfunction (sinus bradycardia or sinus pauses), as an alternative to atrial or dual chamber pacing, when atrial lead placement is considered difficult, high risk, or not deemed necessary for effective therapy The FDA approved the Micra system on the basis of clinical trial evidence from the Micra Investigational Device Exemption (IDE) study (NCT02488681).

On January 18, 2017, the Centers for Medicare and Medicaid Services (CMS) issued a final National Coverage Determination (NCD) on leadless pacemakers, providing for coverage with Coverage with Evidence Development (CED) of approved leadless pacemakers for approved indications (CAG-00448N). The NCD requires the research study conducted as part of CED to address the following research questions:

  1. What are the peri-procedural and post-procedural complications of leadless pacemakers?
  2. What are the long-term outcomes of leadless pacemakers?
  3. What are the effects of patient characteristics (age, gender, comorbidities) on the use and health effects of leadless pacemakers?

In addition, CMS outlined six evidentiary gaps in the final NCD for leadless pacemakers:

  1. What are the peri-procedural and post-procedural complications, and long term outcomes of leadless pacemakers?
  2. Are leadless pacemakers equivalent or superior to conventional pacemaker's in general clinical practice?
  3. What are the infection rates, the long-term hemodynamic effects, and the rates of formation of thrombi?
  4. What are the patient demographics and effects of patient characteristics (age, gender, comorbidities) on the use and health effects of leadless pacemakers?
  5. What are the device-related issues (handling of end of battery life; effects of having multiple leadless pacemakers implanted; rate of device dislodgement; and the possibility of device extractions)?
  6. How are operators and facility characteristics related to peri-procedural and post-procedural complications?

Details
Condition Pacemaker
Treatment Micra Transcatheter Pacemaker System
Clinical Study IdentifierNCT04051814
SponsorHoag Memorial Hospital Presbyterian
Last Modified on14 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

All Patients scheduled to be implanted with a leadless pacemaker

Exclusion Criteria

\-
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note